-
1
-
-
0024595925
-
Clinical pharmacology of 5-fluorouracil
-
Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237.
-
(1989)
Clin Pharmacokinet
, vol.16
, pp. 215-237
-
-
Diasio, R.B.1
Harris, B.E.2
-
2
-
-
0026753035
-
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
-
Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899-2902.
-
(1992)
Cancer Res
, vol.52
, pp. 2899-2902
-
-
Fleming, R.A.1
Milano, G.2
Thyss, A.3
Etienne, M.C.4
Renee, N.5
Schneider, M.6
-
3
-
-
0025058867
-
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
-
Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
-
(1990)
Cancer Res
, vol.50
, pp. 197-201
-
-
Harris, B.E.1
Song, R.2
Soong, S.J.3
Diasio, R.B.4
-
4
-
-
0028006858
-
Population study of dihydropyrimidine dehydrogenase in cancer patients
-
Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-2253.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2248-2253
-
-
Etienne, M.C.1
Lagrange, J.L.2
Dassonville, O.3
Fleming, R.4
Thyss, A.5
Renee, N.6
-
5
-
-
0037144354
-
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g4a mutation
-
van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g4a mutation. Int J Cancer 2002; 101: 253-258.
-
(2002)
Int J Cancer
, vol.101
, pp. 253-258
-
-
Van Kuilenburg, A.B.1
Meinsma, R.2
Zoetekouw, L.3
Van Gennip, A.H.4
-
6
-
-
33646466916
-
Toxic death-case after capecitabine+oxaliplatin (XELOX) administration: Probable implication of dihydropyrimidine deshydrogenase deficiency
-
Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K et al. Toxic death-case after capecitabine+oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 2006; 58: 272-275.
-
(2006)
Cancer Chemother Pharmacol
, vol.58
, pp. 272-275
-
-
Ciccolini, J.1
Mercier, C.2
Dahan, L.3
Evrard, A.4
Boyer, J.C.5
Richard, K.6
-
7
-
-
0037041639
-
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
-
Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86: 1028-1033.
-
(2002)
Br J Cancer
, vol.86
, pp. 1028-1033
-
-
Maring, J.G.1
Van Kuilenburg, A.B.2
Haasjes, J.3
Piersma, H.4
Groen, H.J.5
Uges, D.R.6
-
8
-
-
84857074749
-
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G4A mutation in DPYD by means of a Bayesian limited sampling strategy
-
van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G4A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012; 51: 163-174.
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 163-174
-
-
Van Kuilenburg, A.B.1
Hausler, P.2
Schalhorn, A.3
Tanck, M.W.4
Proost, J.H.5
Terborg, C.6
-
9
-
-
36549011401
-
Severe or lethal toxicities upon capecitabine intake: Is DPYD genetic polymorphism the ideal culprit?
-
Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 2007; 28: 597-598.
-
(2007)
Trends Pharmacol Sci
, vol.28
, pp. 597-598
-
-
Mercier, C.1
Ciccolini, J.2
-
10
-
-
78651086494
-
DPDbased adaptive dosing of 5-FU in patients with head and neck cancer: Impact on treatment efficacy and toxicity
-
Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C et al. DPDbased adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67: 49-56.
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 49-56
-
-
Yang, C.G.1
Ciccolini, J.2
Blesius, A.3
Dahan, L.4
Bagarry-Liegey, D.5
Brunet, C.6
-
11
-
-
0034901306
-
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G4A mutation causing DPD deficiency
-
van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G4A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1149-1153
-
-
Van Kuilenburg, A.B.1
Muller, E.W.2
Haasjes, J.3
Meinsma, R.4
Zoetekouw, L.5
Waterham, H.R.6
-
12
-
-
0031912432
-
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
-
Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4: 325-329.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 325-329
-
-
Lu, Z.1
Zhang, R.2
Carpenter, J.T.3
Diasio, R.B.4
-
13
-
-
33947416573
-
5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency
-
Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007; 249: 271-282.
-
(2007)
Cancer Lett
, vol.249
, pp. 271-282
-
-
Boisdron-Celle, M.1
Remaud, G.2
Traore, S.3
Poirier, A.L.4
Gamelin, L.5
Morel, A.6
-
15
-
-
0022400840
-
Enzymes of uracil catabolism in normal and neoplastic human tissues
-
Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-5412.
-
(1985)
Cancer Res
, vol.45
, pp. 5405-5412
-
-
Naguib, F.N.1
El Kouni, M.H.2
Cha, S.3
-
16
-
-
0027426408
-
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
-
Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-5438.
-
(1993)
Cancer Res
, vol.53
, pp. 5433-5438
-
-
Lu, Z.1
Zhang, R.2
Diasio, R.B.3
-
17
-
-
33947363293
-
HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity
-
van Kuilenburg AB, van LH, Zoetekouw L, Kulik W. HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity. Clin Chem 2007; 53: 528-530.
-
(2007)
Clin Chem
, vol.53
, pp. 528-530
-
-
Van Kuilenburg, A.B.1
Van Lh Zoetekouw, L.2
Kulik, W.3
-
18
-
-
0033967318
-
Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency
-
van Kuilenburg AB, van LH, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000; 46: 9-17.
-
(2000)
Clin Chem
, vol.46
, pp. 9-17
-
-
Van Kuilenburg, A.B.1
Van Lh Tromp, A.2
Veltman, P.C.3
Van Gennip, A.H.4
-
19
-
-
0030885948
-
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity
-
Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696: 183-191.
-
(1997)
J Chromatogr B Biomed Sci Appl
, vol.696
, pp. 183-191
-
-
Johnson, M.R.1
Yan, J.2
Shao, L.3
Albin, N.4
Diasio, R.B.5
-
20
-
-
0032867125
-
Severe 5-fluorouracil-induced toxicity due to increased dihydropyrimidine dehydrogenase activity: Report of a patient survival and urinary pyrimidine and dihydropyrimidine levels
-
Dobashi K, Ohe E, Yamaguchi K, Takeshita S, Ayabe T, Miyazaki M et al. Severe 5-fluorouracil-induced toxicity due to increased dihydropyrimidine dehydrogenase activity: report of a patient survival and urinary pyrimidine and dihydropyrimidine levels. Int J Clin Oncol 1999; 4: 241-243.
-
(1999)
Int J Clin Oncol
, vol.4
, pp. 241-243
-
-
Dobashi, K.1
Ohe, E.2
Yamaguchi, K.3
Takeshita, S.4
Ayabe, T.5
Miyazaki, M.6
-
21
-
-
68449102453
-
A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells
-
Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P et al. A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 2009; 31: 482-488.
-
(2009)
Ther Drug Monit
, vol.31
, pp. 482-488
-
-
Lostia, A.M.1
Lionetto, L.2
Ialongo, C.3
Gentile, G.4
Viterbo, A.5
Malaguti, P.6
-
22
-
-
0036582029
-
Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semiautomated HPLC-radioassay
-
Liem LK, Choong LH, Woo KT. Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semiautomated HPLC-radioassay. Clin Biochem 2002; 35: 181-187.
-
(2002)
Clin Biochem
, vol.35
, pp. 181-187
-
-
Liem, L.K.1
Choong, L.H.2
Woo, K.T.3
-
23
-
-
0034782963
-
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
-
Di PA, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301-1306.
-
(2001)
Ann Oncol
, vol.12
, pp. 1301-1306
-
-
Di Danesi, P.A.R.1
Falcone, A.2
Cionini, L.3
Vannozzi, F.4
Masi, G.5
-
24
-
-
1942502420
-
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test
-
Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004; 10: 2652-2658.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 2652-2658
-
-
Mattison, L.K.1
Ezzeldin, H.2
Carpenter, M.3
Modak, A.4
Johnson, M.R.5
Diasio, R.B.6
-
25
-
-
31544475978
-
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: Pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil
-
Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 2006; 12: 549-555.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 549-555
-
-
Mattison, L.K.1
Fourie, J.2
Hirao, Y.3
Koga, T.4
Desmond, R.A.5
King, J.R.6
-
26
-
-
33749350447
-
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
-
Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12: 5491-5495.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5491-5495
-
-
Mattison, L.K.1
Fourie, J.2
Desmond, R.A.3
Modak, A.4
Saif, M.W.5
Diasio, R.B.6
-
27
-
-
82455209056
-
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
-
van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg AB, Maring JG. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 2011; 68: 1611-1617.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 1611-1617
-
-
Van Staveren, M.C.1
Theeuwes-Oonk, B.2
Guchelaar, H.J.3
Van Kuilenburg, A.B.4
Maring, J.G.5
-
28
-
-
33749828072
-
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy
-
Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006; 28: 678-685.
-
(2006)
Ther Drug Monit
, vol.28
, pp. 678-685
-
-
Ciccolini, J.1
Mercier, C.2
Evrard, A.3
Dahan, L.4
Boyer, J.C.5
Duffaud, F.6
-
29
-
-
0033975442
-
Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase
-
Bi D, Anderson LW, Shapiro J, Shapiro A, Grem JL, Takimoto CH. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatogr B Biomed Sci Appl 2000; 738: 249-258.
-
(2000)
J Chromatogr B Biomed Sci Appl
, vol.738
, pp. 249-258
-
-
Bi, D.1
Anderson, L.W.2
Shapiro, J.3
Shapiro, A.4
Grem, J.L.5
Takimoto, C.H.6
-
30
-
-
69649088627
-
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil
-
Ben FR, Gross E, Ben AS, Hassine H, Saguem S. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Pathol Biol (Paris) 2009; 57: 470-476.
-
(2009)
Pathol Biol (Paris)
, vol.57
, pp. 470-476
-
-
Ben, F.R.1
Gross, E.2
Ben, A.S.3
Hassine, H.4
Saguem, S.5
-
31
-
-
4043162680
-
A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity
-
Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 2004; 29: 307-315.
-
(2004)
J Clin Pharm Ther
, vol.29
, pp. 307-315
-
-
Ciccolini, J.1
Mercier, C.2
Blachon, M.F.3
Favre, R.4
Durand, A.5
Lacarelle, B.6
-
32
-
-
33847721425
-
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients
-
Zhou ZW, Wang GQ, Wan dS, Lu ZH, Chen YB, Li S et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007; 53: 127-131.
-
(2007)
Chemotherapy
, vol.53
, pp. 127-131
-
-
Zhou, Z.W.1
Wang, G.Q.2
Wan, D.S.3
Zh, L.4
Chen, Y.B.5
Li, S.6
-
33
-
-
0032940053
-
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
-
Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1105
-
-
Gamelin, E.1
Boisdron-Celle, M.2
Guerin-Meyer, V.3
Delva, R.4
Lortholary, A.5
Genevieve, F.6
-
34
-
-
0037099750
-
Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential pretreatment predictor of 5-fluorouracil toxicity
-
Garg MB, Sevester JC, Sakoff JA, Ackland SP. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 774: 223-230.
-
(2002)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.774
, pp. 223-230
-
-
Garg, M.B.1
Sevester, J.C.2
Sakoff, J.A.3
Ackland, S.P.4
-
35
-
-
0028828967
-
Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography
-
Sumi S, Kidouchi K, Ohba S, Wada Y. Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 672: 233-239.
-
(1995)
J Chromatogr B Biomed Appl
, vol.672
, pp. 233-239
-
-
Sumi, S.1
Kidouchi, K.2
Ohba, S.3
Wada, Y.4
-
36
-
-
23644444294
-
An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines- related toxicity in clinical practice
-
Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 823: 98-107.
-
(2005)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.823
, pp. 98-107
-
-
Remaud, G.1
Boisdron-Celle, M.2
Hameline, C.3
Morel, A.4
Gamelin, E.5
-
37
-
-
77957732473
-
The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients
-
Kristensen MH, Pedersen P, Mejer J. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 2010; 38: 1313-1323.
-
(2010)
J Int Med Res
, vol.38
, pp. 1313-1323
-
-
Kristensen, M.H.1
Pedersen, P.2
Mejer, J.3
-
38
-
-
1842453897
-
Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: A potential biomarker for dihydropyrimidine dehydrogenase levels
-
Jiang H, Lu J, Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004; 141: 616-623.
-
(2004)
Br J Pharmacol
, vol.141
, pp. 616-623
-
-
Jiang, H.1
Lu, J.2
Ji, J.3
-
39
-
-
20044380148
-
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling
-
Di PA, Danesi R, Ciofi L, Vannozzi F, Bocci G, Lastella M et al. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit 2005; 27: 362-368.
-
(2005)
Ther Drug Monit
, vol.27
, pp. 362-368
-
-
Di Danesi, P.A.R.1
Ciofi, L.2
Vannozzi, F.3
Bocci, G.4
Lastella, M.5
-
40
-
-
0035950466
-
High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: Application to measurement of dihydropyrimidine dehydrogenase activity
-
Deporte-Fety R, Picot M, Amiand M, Moreau A, Campion L, Lanoe D et al. High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 2001; 762: 203-209.
-
(2001)
J Chromatogr B Biomed Sci Appl
, vol.762
, pp. 203-209
-
-
Deporte-Fety, R.1
Picot, M.2
Amiand, M.3
Moreau, A.4
Campion, L.5
Lanoe, D.6
-
41
-
-
24044435224
-
Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma
-
Remaud G, Boisdron-Celle M, Morel A, Gamelin A. Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824: 153-160.
-
(2005)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.824
, pp. 153-160
-
-
Remaud, G.1
Boisdron-Celle, M.2
Morel, A.3
Gamelin, A.4
-
42
-
-
72949093283
-
Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer
-
Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit 2009; 31: 688-694.
-
(2009)
Ther Drug Monit
, vol.31
, pp. 688-694
-
-
Beumer, J.H.1
Boisdron-Celle, M.2
Clarke, W.3
Courtney, J.B.4
Egorin, M.J.5
Gamelin, E.6
-
43
-
-
33749235886
-
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity
-
Bocci G, Barbara C, Vannozzi F, Di PA, Melosi A, Barsanti G et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 2006; 80: 384-395.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 384-395
-
-
Bocci, G.1
Barbara, C.2
Vannozzi, F.3
Di Melosi, P.A.A.4
Barsanti, G.5
-
44
-
-
0033870677
-
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients
-
Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000; 6: 3032-3037.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3032-3037
-
-
Bocci, G.1
Danesi, R.2
Di Paolo, A.D.3
Innocenti, F.4
Allegrini, G.5
Falcone, A.6
-
45
-
-
0036913715
-
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer
-
Di PA, Danesi R, Vannozzi F, Falcone A, Mini E, Cionini L et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627-637.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 627-637
-
-
Di Danesi, P.A.R.1
Vannozzi, F.2
Falcone, A.3
Mini, E.4
Cionini, L.5
-
46
-
-
46749147549
-
Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1 G4A mutation in the dihydropyrimidine dehydrogenase gene
-
van Kuilenburg AB, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1 G4A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 2008; 27: 692-698.
-
(2008)
Nucleosides Nucleotides Nucleic Acids
, vol.27
, pp. 692-698
-
-
Van Kuilenburg, A.B.1
Maring, J.G.2
Schalhorn, A.3
Terborg, C.4
Schmalenberg, H.5
Behnke, D.6
-
47
-
-
0036629198
-
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency
-
Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002; 306: 63-73.
-
(2002)
Anal Biochem
, vol.306
, pp. 63-73
-
-
Ezzeldin, H.1
Okamoto, Y.2
Johnson, M.R.3
Diasio, R.B.4
-
48
-
-
0037477777
-
Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography
-
Fischer J, Schwab M, Eichelbaum M, Zanger UM. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test 2003; 7: 97-105.
-
(2003)
Genet Test
, vol.7
, pp. 97-105
-
-
Fischer, J.1
Schwab, M.2
Eichelbaum, M.3
Zanger, U.M.4
-
49
-
-
10844253317
-
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects
-
Gross E, Ullrich T, Seck K, Mueller V, de Wit WM, von Schilling SC et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498.
-
(2003)
Hum Mutat
, vol.22
, pp. 498
-
-
Gross, E.1
Ullrich, T.2
Seck, K.3
Mueller, V.4
De Wit, W.M.5
Von Schilling, S.C.6
-
50
-
-
0037093447
-
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure
-
van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364: 157-163.
-
(2002)
Biochem J
, vol.364
, pp. 157-163
-
-
Van Kuilenburg, A.B.1
Dobritzsch, D.2
Meinsma, R.3
Haasjes, J.4
Waterham, H.R.5
Nowaczyk, M.J.6
-
51
-
-
79955838788
-
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding
-
Weidensee S, Goettig P, Bertone M, Haas D, Magdolen V, Kiechle M et al. A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding. Clin Biochem 2011; 44: 722-724.
-
(2011)
Clin Biochem
, vol.44
, pp. 722-724
-
-
Weidensee, S.1
Goettig, P.2
Bertone, M.3
Haas, D.4
Magdolen, V.5
Kiechle, M.6
-
52
-
-
0141615759
-
Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase
-
Ahluwalia R, Freimuth R, McLeod HL, Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 2003; 49: 1661-1664.
-
(2003)
Clin Chem
, vol.49
, pp. 1661-1664
-
-
Ahluwalia, R.1
Freimuth, R.2
McLeod, H.L.3
Marsh, S.4
-
53
-
-
69049114190
-
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment
-
Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009; 10: 931-944.
-
(2009)
Pharmacogenomics
, vol.10
, pp. 931-944
-
-
Amstutz, U.1
Farese, S.2
Aebi, S.3
Largiader, C.R.4
-
54
-
-
33845219798
-
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
-
Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895-2904.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 2895-2904
-
-
Morel, A.1
Boisdron-Celle, M.2
Fey, L.3
Soulie, P.4
Craipeau, M.C.5
Traore, S.6
-
55
-
-
0035052703
-
Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes
-
Nauck M, Gierens H, Marz W, Wieland H. Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 2001; 34: 103-105.
-
(2001)
Clin Biochem
, vol.34
, pp. 103-105
-
-
Nauck, M.1
Gierens, H.2
Marz, W.3
Wieland, H.4
-
56
-
-
11144355814
-
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients
-
Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 2004; 6: 102-107.
-
(2004)
Genet Med
, vol.6
, pp. 102-107
-
-
Salgueiro, N.1
Veiga, I.2
Fragoso, M.3
Sousa, O.4
Costa, N.5
Pellon, M.L.6
-
57
-
-
0034488052
-
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
-
van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, van LH, De Abreu RA et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4705-4712
-
-
Van Kuilenburg, A.B.1
Haasjes, J.2
Richel, D.J.3
Zoetekouw, L.4
Van, L.H.5
De Abreu, R.A.6
-
58
-
-
79955998006
-
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer
-
Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17: 3455-3468.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3455-3468
-
-
Deenen, M.J.1
Tol, J.2
Burylo, A.M.3
Doodeman, V.D.4
De Boer, A.5
Vincent, A.6
-
59
-
-
78049435885
-
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
-
van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010; 128: 529-538.
-
(2010)
Hum Genet
, vol.128
, pp. 529-538
-
-
Van Kuilenburg, A.B.1
Meijer, J.2
Mul, A.N.3
Meinsma, R.4
Schmid, V.5
Dobritzsch, D.6
-
60
-
-
0032974922
-
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
-
van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, van LH et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9.
-
(1999)
Hum Genet
, vol.104
, pp. 1-9
-
-
Van Kuilenburg, A.B.1
Vreken, P.2
Abeling, N.G.3
Bakker, H.D.4
Lh Van, M.R.5
-
61
-
-
82455199207
-
Severe fluoropyrimidine-related toxicity: Clinical implications of DPYD analysis and UH2/U ratio evaluation
-
Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D'Amico M et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol 2011; 68: 1355-1361.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 1355-1361
-
-
Giorgio, E.1
Caroti, C.2
Mattioli, F.3
Uliana, V.4
Parodi, M.I.5
D'amico, M.6
-
62
-
-
34447321898
-
Dihydropyrimidine dehydrogenase activity and the IVS14+1G4A mutation in patients developing 5FU-related toxicity
-
Magne N, Etienne-Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G4A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 2007; 64: 237-240.
-
(2007)
Br J Clin Pharmacol
, vol.64
, pp. 237-240
-
-
Magne, N.1
Etienne-Grimaldi, M.C.2
Cals, L.3
Renee, N.4
Formento, J.L.5
Francoual, M.6
-
63
-
-
35449005887
-
SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit
-
Okamoto Y, Ueta A, Sumi S, Ito T, Okubo Y, Jose Y et al. SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit. Biochem Genet 2007; 45: 713-724.
-
(2007)
Biochem Genet
, vol.45
, pp. 713-724
-
-
Okamoto, Y.1
Ueta, A.2
Sumi, S.3
Ito, T.4
Okubo, Y.5
Jose, Y.6
-
64
-
-
29344443013
-
Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients
-
Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11: 8699-8705.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8699-8705
-
-
Ezzeldin, H.H.1
Lee, A.M.2
Mattison, L.K.3
Diasio, R.B.4
-
65
-
-
6044238251
-
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells
-
Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004; 10: 7100-7107.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7100-7107
-
-
Noguchi, T.1
Tanimoto, K.2
Shimokuni, T.3
Ukon, K.4
Tsujimoto, H.5
Fukushima, M.6
-
66
-
-
56349087342
-
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
-
Amstutz U, Farese S, Aebi S, Largiader CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 2008; 27: 54.
-
(2008)
J Exp Clin Cancer Res
, vol.27
, pp. 54
-
-
Amstutz, U.1
Farese, S.2
Aebi, S.3
Largiader, C.R.4
-
67
-
-
77956472030
-
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients
-
Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M, Costa VL, Rodrigues A, Dias PC et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 2010; 10: 470.
-
(2010)
BMC Cancer
, vol.10
, pp. 470
-
-
Savva-Bordalo, J.1
Ramalho-Carvalho, J.2
Pinheiro, M.3
Costa, V.L.4
Rodrigues, A.5
Dias, P.C.6
-
68
-
-
0034808681
-
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 50-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
-
Raida M, Schwabe W, Hausler P, van Kuilenburg AB, Van Gennip AH, Behnke D et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 50-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832-2839.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2832-2839
-
-
Raida, M.1
Schwabe, W.2
Hausler, P.3
Van Kuilenburg, A.B.4
Van Gennip, A.H.5
Behnke, D.6
-
69
-
-
23844456590
-
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals
-
Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11: 5886-5892.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5886-5892
-
-
Seck, K.1
Riemer, S.2
Kates, R.3
Ullrich, T.4
Lutz, V.5
Harbeck, N.6
-
70
-
-
0034651781
-
Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction
-
Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278: 175-184.
-
(2000)
Anal Biochem
, vol.278
, pp. 175-184
-
-
Johnson, M.R.1
Wang, K.2
Smith, J.B.3
Heslin, M.J.4
Diasio, R.B.5
-
71
-
-
0036798968
-
High prevalence of the IVS14+1G4A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
-
van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14+1G4A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555-558.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 555-558
-
-
Van Kuilenburg, A.B.1
Meinsma, R.2
Zoetekouw, L.3
Van Gennip, A.H.4
-
72
-
-
43749114271
-
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group
-
Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2131-2138
-
-
Schwab, M.1
Zanger, U.M.2
Marx, C.3
Schaeffeler, E.4
Klein, K.5
Dippon, J.6
-
73
-
-
13344269002
-
Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
-
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441-451.
-
(1996)
Cancer
, vol.77
, pp. 441-451
-
-
Gamelin, E.C.1
Danquechin-Dorval, E.M.2
Dumesnil, Y.F.3
Maillart, P.J.4
Goudier, M.J.5
Burtin, P.C.6
-
74
-
-
0032956515
-
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: Major implications for the detection of partly deficient patients
-
van Kuilenburg AB, van LH, Blom MJ, Mul EP, Van Gennip AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999; 79: 620-626.
-
(1999)
Br J Cancer
, vol.79
, pp. 620-626
-
-
Van Kuilenburg, A.B.1
Van Lh Blom, M.J.2
Mul, E.P.3
Van Gennip, A.H.4
|